###begin article-title 0
###xml 100 108 <span type="species:ncbi:9606">patients</span>
The relationship between gastric emptying, plasma cholecystokinin, and peptide YY in critically ill patients
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 238 246 <span type="species:ncbi:9606">patients</span>
Cholecystokinin (CCK) and peptide YY (PYY) are released in response to intestinal nutrients and play an important physiological role in regulation of gastric emptying (GE). Plasma CCK and PYY concentrations are elevated in critically ill patients, particularly in those with a history of feed intolerance. This study aimed to evaluate the relationship between CCK and PYY concentrations and GE in critical illness.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 22 26 22 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 72 74 70 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 208 210 204 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 212 214 208 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 144 152 <span type="species:ncbi:9606">patients</span>
GE of 100 mL of Ensure(R) meal (106 kcal, 21% fat) was measured using a 13C-octanoate breath test in 39 mechanically ventilated, critically ill patients (24 males; 55.8 +/- 2.7 years old). Breath samples for 13CO2 levels were collected over the course of 4 hours, and the GE coefficient (GEC) (normal = 3.2 to 3.8) was calculated. Measurements of plasma CCK, PYY, and glucose concentrations were obtained immediately before and at 60 and 120 minutes after administration of Ensure.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 107 109 103 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 168 170 160 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 278 280 270 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 289 291 281 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 308 310 300 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 319 321 311 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 375 377 367 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 394 396 386 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 524 526 516 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 534 536 526 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 553 555 545 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 563 565 555 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 37 45 <span type="species:ncbi:9606">patients</span>
###xml 208 216 <span type="species:ncbi:9606">patients</span>
###xml 434 442 <span type="species:ncbi:9606">patients</span>
GE was delayed in 64% (25/39) of the patients. Baseline plasma CCK (8.5 +/- 1.0 versus 6.1 +/- 0.4 pmol/L; P = 0.045) and PYY (22.8 +/- 2.2 versus 15.6 +/- 1.3 pmol/L; P = 0.03) concentrations were higher in patients with delayed GE and were inversely correlated with GEC (CCK: r = -0.33, P = 0.04, and PYY: r = -0.36, P = 0.02). After gastric Ensure, while both plasma CCK (P = 0.03) and PYY (P = 0.02) concentrations were higher in patients with delayed GE, there was a direct relationship between the rise in plasma CCK (r = 0.40, P = 0.01) and PYY (r = 0.42, P < 0.01) from baseline at 60 minutes after the meal and the GEC.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
In critical illness, there is a complex interaction between plasma CCK, PYY, and GE. Whilst plasma CCK and PYY correlated moderately with impaired GE, the pathogenetic role of these gut hormones in delayed GE requires further evaluation with specific antagonists.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 190 191 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 192 193 192 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 466 467 466 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 468 469 468 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 551 552 551 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 778 779 778 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 780 781 780 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 782 783 782 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 784 785 784 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 786 788 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 789 791 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 828 829 828 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 830 831 830 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 832 834 832 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 835 837 835 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 916 918 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 919 921 919 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1141 1143 1141 1143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1144 1146 1144 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1230 1232 1230 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1233 1235 1233 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 569 575 <span type="species:ncbi:9606">humans</span>
###xml 908 914 <span type="species:ncbi:9606">humans</span>
###xml 963 969 <span type="species:ncbi:9606">humans</span>
###xml 1061 1069 <span type="species:ncbi:9606">patients</span>
In health, cholecystokinin (CCK) and peptide YY (PYY) are important humoral mediators of nutrient-induced small intestinal feedback, which regulates gastric emptying (GE) and energy intake [1-5]. In response to the presence of nutrients (particularly fat and protein) in the small intestine, CCK and PYY are released in a load-dependent manner from enteroendocrine cells, predominantly in the proximal small intestine for CCK and the distal small intestine for PYY [5-8]. CCK has also been reported to mediate the initial postprandial release of PYY [9,10]. In healthy humans, exogenous administration of CCK and PYY is associated with relaxation of the proximal stomach, inhibition of antral motor activity, stimulation of contractions localised to the pylorus, slowing of GE [1,2,4,7,11,12], and a reduction in energy intake [3,4,13-16]. CCK antagonists have been shown to increase GE and energy intake in humans [17-19]. The effects of PYY antagonism on GE in humans, however, are unknown. Furthermore, both plasma CCK and PYY concentrations are elevated in patients with chronic nutrient deprivation, malnutrition, and anorexia nervosa [20-22], conditions that are known to be associated with a high prevalence of delayed GE [23,24].
###end p 11
###begin p 12
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 713 715 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 716 718 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 903 905 903 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 906 908 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1091 1093 1091 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1094 1096 1094 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1097 1099 1097 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
###xml 585 593 <span type="species:ncbi:9606">patients</span>
###xml 677 685 <span type="species:ncbi:9606">patients</span>
###xml 1081 1089 <span type="species:ncbi:9606">patients</span>
Impaired gastric motor function and associated feed intolerance occur in up to 50% of critically ill patients and can adversely affect both morbidity and mortality [25,26]. Whilst the mechanisms underlying delayed GE in critical illness remain poorly defined, exaggerated inhibitory feedback on GE arising from the interaction of nutrients with the small intestine is likely to be important [27]. For example, in response to duodenal nutrient, there is a greater degree of antral hypo-motility, pyloric hyperactivity [27], and exaggerated release of both CCK and PYY in critically ill patients [28,29]. Furthermore, the CCK and PYY responses are substantially greater in those patients who have feed intolerance [28,29]. In the fasted state, there is an increase in plasma concentrations of hormones that slow GE, such as CCK and PYY, and a decrease in hormones that may accelerate GE, such as ghrelin [28-30]. The effects of exogenous CCK and PYY on gastric motility are also comparable to the motor disturbances in both the proximal and distal stomach observed in critically ill patients [27,31,32].
###end p 12
###begin p 13
Whereas the above evidence supports a potential role for both CCK and PYY in the mediation of enhanced nutrient-induced enterogastric feedback during critical illness, the relationships between plasma CCK and PYY concentrations and GE in critical illness have hitherto not been evaluated. This study was designed to examine the following hypotheses: (a) slow GE is associated with elevated plasma concentrations of CCK and PYY, and (b) GE is a determinant of postprandial concentrations of CCK and PYY in the critically ill.
###end p 13
###begin title 14
Materials and methods
###end title 14
###begin title 15
Subjects
###end title 15
###begin p 16
###xml 840 842 838 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 843 845 841 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 846 848 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
###xml 210 217 <span type="species:ncbi:9606">patient</span>
###xml 671 679 <span type="species:ncbi:9606">patients</span>
###xml 918 926 <span type="species:ncbi:9606">patients</span>
###xml 992 997 <span type="species:ncbi:9606">Human</span>
###xml 1185 1193 <span type="species:ncbi:9606">patients</span>
Studies were performed prospectively in 39 unselected critically ill patients (24 males; 55.8 +/- 2.7 years old) who were admitted to a level-3 intensive care unit (ICU) between May 2005 and November 2006. Any patient at least 17 years old was eligible for inclusion if he or she was sedated, mechanically ventilated, and able to receive enteral nutrition. Exclusion criteria included any contraindication to passage of an enteral tube; a history of gastric, oesophageal, or intestinal surgery; recent major abdominal surgery; evidence of liver dysfunction; administration of prokinetic therapy within 24 hours prior to the study; and a history of diabetes mellitus. All patients were receiving an insulin infusion according to a standard protocol, which was designed to maintain the blood glucose concentration between 5.0 and 7.9 mmol/L [27-29,31]. Written informed consent was obtained from the next of kin for all patients prior to enrolment into the study. The study was approved by the Human Research Ethics Committee of the Royal Adelaide Hospital and performed according to the National Health and Medical Research Council guidelines for the conduct of research on unconscious patients.
###end p 16
###begin title 17
Study protocol and techniques
###end title 17
###begin p 18
###xml 464 472 464 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 299 306 <span type="species:ncbi:9606">patient</span>
###xml 329 336 <span type="species:ncbi:9606">patient</span>
###xml 355 363 <span type="species:ncbi:9606">patients</span>
Critically ill patients were studied in the morning, after a minimum 8-hour fast. All patients were sedated, with either propofol or a combination of morphine and midazolam, throughout a minimum of 24 hours prior to the study. The type of sedation was determined by the intensivist in charge of the patient and did not influence patient selection. In all patients, a 14- to 16-French gauge Levin nasogastric feeding tube (Pharma-Plast, Lynge, Denmark) was already in situ in the stomach, as part of clinical care, and the correct position of the feeding tube was confirmed radiologically prior to commencing the study.
###end p 18
###begin p 19
###xml 21 23 21 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 353 355 337 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 808 811 792 793 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 1005 1007 987 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 57 64 <span type="species:ncbi:9606">patient</span>
###xml 1231 1238 <span type="species:ncbi:9606">patient</span>
GE was measured by a 13C-octanoate breath test, with the patient in the supine position and the head of the bed elevated to 30degrees. Gastric contents were initially aspirated and discarded, and then 100 mL of liquid nutrient meal (Ensuretrade mark; Abbott Australia, Kurnell, Australia) containing 106 kcal with 21% of fat and labelled with 100 muL of13C-octanoate (100 mg/mL; Cambridge Isotope Laboratories, Inc., Andover, MA, USA) was infused slowly over the course of 5 minutes into the stomach via the nasogastric tube. End-expiratory breath samples were obtained from the ventilation tube using a T-adapter (Datex-Engstrom, now part of GE Healthcare, Little Chalfont, Buckinghamshire, UK) and holder for vacutainers (blood needle holder; Reko Pty Ltd, Lisarow, Australia) containing a needle (VenoJect(R); Terumo Corporation, Tokyo, Japan). Samples were collected at baseline, every 5 minutes for the first hour, and every 15 minutes thereafter, for a subsequent 3 hours after meal administration [33]. Time (t) = 0 minutes was defined as the time when all of the Ensure had been infused into the stomach. To avoid sampling other than end-expiratory air, sampling was timed to the end-expiratory phase by observation of the patient and the time-flow curve on the ventilation monitor.
###end p 19
###begin p 20
Blood samples (5 mL) for the measurement of plasma CCK and PYY were collected into chilled EDTA (ethylenediaminetetraacetic acid) tubes immediately before and at 60 and 120 minutes after the delivery of the intragastric meal. Blood samples were centrifuged at 4degreesC within 30 minutes of collection and stored at -70degreesC for subsequent analysis. Blood samples for the measurement of blood glucose were also collected at baseline, every 15 minutes for the first hour, and every 30 minutes for the subsequent 3 hours.
###end p 20
###begin title 21
Measurements
###end title 21
###begin title 22
Gastric emptying
###end title 22
###begin p 23
###xml 36 38 36 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 219 227 <span type="species:ncbi:9606">patients</span>
###xml 255 263 <span type="species:ncbi:9606">patients</span>
GE was assessed indirectly by using 13C-octanoate breath tests. This non-invasive technique has been validated against gastric scintigraphy, using both solid and liquid meals, in healthy subjects and non-critically ill patients [34-39]. In critically ill patients, the breath test has a sensitivity of 71% and a specificity of 100% in detecting delayed GE, with a modest correlation between gastric half-emptying time determined by breath test and scintigraphy [40].
###end p 23
###begin p 24
###xml 23 25 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 47 49 47 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 51 53 51 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 213 215 213 215 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 302 304 302 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 306 308 306 308 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 481 483 481 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">at</italic>
###xml 483 484 483 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 483 484 483 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>b</italic></sup>
###xml 484 486 484 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e </italic>
###xml 487 489 487 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et</italic>
###xml 486 489 486 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-<italic>et</italic></sup>
###xml 520 522 520 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 524 526 524 526 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 635 637 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 810 812 810 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
The concentration of CO2 and the percentage of 13CO2 were measured in each sample by means of an isotope ratio mass spectrometer (ABCA model 20/20; Europa Scientific, Crewe, UK). Samples containing less than 1% CO2 were regarded as being non-end-expiratory and were excluded from further analysis. The 13CO2 concentration over time was plotted, and the resultant curves were used to calculate a GE coefficient (GEC) [41], using non-linear regression formulae: GEC = ln(y)) and y = atbe -et, where y is the percentage of 13CO2 excretion in breaths per hour, t is time in hours, and a, b, and c are regression estimated constants [36,38,42]. GEC is a global index for the GE rate, and the normal range for normal GE has been established previously in a group of 28 healthy volunteers (normal GEC = 3.2 and 3.8) [33].
###end p 24
###begin title 25
Plasma cholecystokinin, peptide YY, and blood glucose
###end title 25
###begin p 26
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 230 237 <span type="species:ncbi:9986">rabbits</span>
###xml 467 472 <span type="species:ncbi:9606">human</span>
Plasma CCK concentrations were measured by radioimmunoassay using an adaptation of the method of Santangelo and colleagues [43]. A commercially available antibody (C2581, lot 105H4852; Sigma-Aldrich, St. Louis, MO, USA) raised in rabbits against synthetic sulphated CCK-8 was used. This antibody binds to all CCK peptides containing the sulphated tyrosine residue in position 7 and has 26% cross-reactivity with un-sulphated CCK-8, less than 2% cross-reactivity with human gastrin 1, and no cross-reactivity with structurally unrelated peptides. Antibody was added at a dilution of 1:17,500, and iodine-125-labeled sulphated CCK-8 with Bolton-Hunter reagent (74 TBq/mmol; Amersham International, now part of GE Healthcare) was used as a tracer. Incubation proceeded for 7 days at 4degreesC. The antibody-bound fraction was separated by the addition of dextran-coated charcoal containing gelatin (0.015 g gelatin, 0.09 g dextran, and 0.15 g charcoal in 30 mL of assay buffer). The detection limit was 1 pmol/L, and the intra-assay coefficient of variation at 50 pmol/L was 9.5%.
###end p 26
###begin p 27
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1635 1637 1613 1615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 89 96 <span type="species:ncbi:9986">rabbits</span>
###xml 105 110 <span type="species:ncbi:9606">human</span>
###xml 205 210 <span type="species:ncbi:9606">human</span>
###xml 288 293 <span type="species:ncbi:9606">human</span>
###xml 404 409 <span type="species:ncbi:9606">human</span>
Plasma PYY concentrations were measured by radioimmunoassay using an antiserum raised in rabbits against human PYY (1-36) (Sigma-Aldrich) [43]. This antiserum showed less than 0.001% cross-reactivity with human pancreatic polypeptide and sulphated CCK-8 and 0.0025% cross-reactivity with human neuropeptide Y. Tracer (Prosearch International, Malvern, Australia) was prepared by radio-labeling synthetic human PYY (1-36) (Auspep Pty Ltd, Parkville, Australia) using the lactoperoxidase method. Mono-iodo-tyrosine-PYY was separated from free iodine-125, diiodo-PYY, and unlabeled PYY by reverse-phase high-performance liquid chromatography (Phenomenex Jupiter C4 300A 5u column catalogue number 00B-4167-EO 250 _ 4.6 mm; Phenomenex, Inc., Torrance, CA, USA). Standards (1.6 to 50 fmol/tube) or samples (200 muL of plasma) were incubated in assay buffer with 100 muL of antiserum at a final dilution of 1:10,000 for 20 to 24 hours at 4degreesC, 100 muL of iodinated PYY (10,000 cpm) was then added, and the incubation continued for another 20 to 24 hours. Separation of the antibody-bound tracer from free tracer was achieved by the addition of 200 muL of dextran-coated charcoal containing gelatin (0.015 g of gelatin, 0.09 g of dextran, and 0.15 g of charcoal per 30 mL of assay buffer) and the mixture was incubated at 4degreesC for 20 minutes and then centrifuged at 4degreesC for 25 minutes. Radioactivity of the bound fraction was determined by counting the supernatants in a gamma counter. The intra- and inter-assay coefficients of variation were 12.3% and 16.6%, respectively. The minimum detectable concentration was 4 pmol/L [43]. Blood glucose concentrations were measured by means of a portable glucometer (Precision Plus; Abbott Laboratories, Abbott Park, IL, USA).
###end p 27
###begin title 28
Statistical analysis
###end title 28
###begin p 29
###xml 202 211 200 209 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0&#8211;120 min</sub>
###xml 346 356 344 354 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0&#8211;120 min </sub>
###xml 450 452 448 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 801 810 799 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">post hoc </italic>
###xml 1087 1089 1085 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1190 1192 1188 1190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 645 653 <span type="species:ncbi:9606">patients</span>
Data are presented as mean +/- standard error of the mean. The integrated changes in plasma concentrations of CCK and PYY were calculated and expressed as areas under the curve over the 120 minutes (AUC0-120 min) after the Ensure meal. Differences in demographic characteristics, in baseline blood glucose, CCK, and PYY concentrations, and in AUC0-120 min for plasma CCK and PYY between critically ill groups were compared using the Student unpaired t test and the chi-square test. Changes in plasma concentrations of CCK and PYY over time were determined by one-way repeated measures analysis of variance (ANOVA). Potential differences between patients with normal versus delayed GE with respect to the plasma CCK, PYY, and blood glucose responses to the meal were evaluated using two-way ANOVA with post hoc analyses. The relationships between GE with baseline plasma CCK and PYY, changes in plasma CCK and PYY (from baseline to t = 60 minutes and t = 120 minutes), and demographic factors (age, body mass index [BMI], Acute Physiology and Chronic Health Evaluation [APACHE] II score [41], and serum creatinine) were assessed using the Pearson correlation. Significance was accepted at a P value of less than 0.05.
###end p 29
###begin title 30
Results
###end title 30
###begin p 31
###xml 115 117 113 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 137 139 135 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 154 156 152 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 184 186 182 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 209 211 207 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 236 238 234 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 258 260 256 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 293 295 291 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 1266 1268 1256 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1415 1417 1401 1403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 373 381 <span type="species:ncbi:9606">patients</span>
###xml 437 445 <span type="species:ncbi:9606">patients</span>
###xml 476 484 <span type="species:ncbi:9606">patients</span>
###xml 644 652 <span type="species:ncbi:9606">patients</span>
###xml 699 707 <span type="species:ncbi:9606">patients</span>
###xml 806 814 <span type="species:ncbi:9606">patients</span>
###xml 950 958 <span type="species:ncbi:9606">patients</span>
###xml 1042 1050 <span type="species:ncbi:9606">patients</span>
###xml 1116 1124 <span type="species:ncbi:9606">patients</span>
The duration of ICU stay prior to the study was 4.60 +/- 0.34 days. The admission diagnoses included multi-trauma (n = 12), head injury (n = 12), sepsis (n = 11), respiratory failure (n = 9), cardiac failure (n = 3), aortic dissection (n = 3), pancreatitis (n = 1), and retroperitoneal bleed (n = 1). The mean APACHE II score on the study day was 22.4 +/- 0.9. Twenty-five patients (64%) were sedated with morphine and midazolam, and 14 patients (36%) with propofol. Nineteen patients (48%) required inotropic support with either adrenaline or noradrenalin. Acid suppression therapy (ranitidine or pantoprazole) was given to 32 (82%) of the 39 patients. Renal function was normal in the majority of patients (82%; 32/39) at the time of study, with a serum creatinine of 0.10 +/- 0.01 mmol/L. None of the 7 patients with renal impairment (mean serum creatinine = 0.23 +/- 0.04 mmol/L) required haemodialysis. Before enrolment into the study, 24 (66%) patients had received enteral feeds for a mean duration of 3.52 +/- 0.36 days, and 15 (34%) patients had not received any nutritional support prior to the study. Ten patients (42%) who received prior enteral nutrition had feed intolerance, defined as aspirates of greater than 250 mL during gastric enteral feeding [44]. The mean duration of ICU stay prior to the study did not differ between the two groups (fed: 4.9 +/- 0.5 days versus not fed: 4.2 +/- 0.4 days; P = 0.78).
###end p 31
###begin title 32
Gastric emptying
###end title 32
###begin p 33
###xml 186 187 184 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 240 242 238 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 259 261 257 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 275 277 273 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 320 322 318 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 579 581 573 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 724 726 718 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 37 45 <span type="species:ncbi:9606">patients</span>
###xml 123 131 <span type="species:ncbi:9606">patients</span>
###xml 687 695 <span type="species:ncbi:9606">patients</span>
GE was delayed in 64% (25/39) of the patients, with a mean GEC of 2.8 +/- 0.1. The demographic data and characteristics of patients who had normal and delayed GE are summarised in Table 1. There was no relationship between the GEC and age (P = 0.23), gender (P = 0.82), BMI (P = 0.86), APACHE II score at time of study (P = 0.68), type of sedation, use of inotropes or acid suppression, presence of sepsis, or prior enteral feeding. The mean fasting blood glucose concentration was 7.14 +/- 0.24 mmol/L, which increased slightly after the meal to a peak of 8.13 +/- 0.28 mmol/L (P < 0.01). There were no differences in either fasting or postprandial blood glucose concentrations between patients with delayed and normal GE (P > 0.05).
###end p 33
###begin p 34
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Demographic data and characteristics of critically ill patients, classified according to their rate of gastric emptying
###end p 34
###begin p 35
###xml 46 47 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 101 102 99 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 51 58 <span type="species:ncbi:9606">patient</span>
Data are mean +/- standard error of the mean. aOne patient may have one or more admission diagnoses. bIncluding sub-arachnoid haemorrhage and massive cerebral ischemic event. APACHE II, Acute Physiology and Chronic Health Evaluation II; CCK, cholecystokinin; GE, gastric emptying; PYY, peptide YY.
###end p 35
###begin title 36
Plasma cholecystokinin and peptide YY concentrations
###end title 36
###begin p 37
###xml 157 159 153 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 167 169 163 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 186 188 182 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 196 198 192 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 286 288 282 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 335 337 331 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 364 366 360 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 554 556 550 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Baseline plasma CCK concentration was 7.74 +/- 0.87 pmol/L and PYY was 20.4 +/- 2.0 pmol/L. Baseline plasma PYY, but not CCK, was positively related to age (r = 0.37; P = 0.01) and BMI (r = 0.50; P < 0.01). Baseline plasma concentrations of both CCK and PYY were not related to gender (P = 0.82), the APACHE II score on the study day (P = 0.40), serum creatinine (P = 0.28), the type of sedation, the use of inotropes or acid suppression, the presence of sepsis, or prior enteral nutrition. There was no relationship between baseline plasma CCK and PYY (P = 0.80).
###end p 37
###begin p 38
###xml 95 97 95 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 155 157 155 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 165 167 165 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 591 592 591 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 637 639 637 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 654 655 654 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 781 783 781 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 791 793 791 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 611 619 <span type="species:ncbi:9606">patients</span>
In response to the gastric meal, there was a small but significant rise in plasma CCK and PYY (P = 0.01) (Figure 1). The integrated changes in plasma CCK (r = 0.45; P < 0.001), but not PYY, from baseline to 120 minutes were positively correlated with age. There was no relationship between integrated plasma CCK or PYY with gender, BMI, APACHE II scores on study day, serum creatinine, the type of sedation, the use of inotropes and acid suppression, presence of sepsis, or prior history of receiving enteral nutrition. Both plasma CCK and PYY remained above baseline at 120 minutes (Figure 1), particularly in patients with delayed GE (P < 0.05) (Table 1). There was a positive correlation between the magnitude of the increase in plasma PYY and CCK concentrations at 60 minutes (r = 0.33; P = 0.03).
###end p 38
###begin p 39
###xml 211 213 209 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
Plasma cholecystokinin (CCK) and peptide YY (PYY) concentrations at baseline and after intragastric Ensure (100 mL, 106 kcal with 21% lipid) in 39 critically ill patients (mean +/- standard error of the mean). *P < 0.05 versus baseline.
###end p 39
###begin title 40
Relationship between gastric emptying, plasma cholecystokinin, and peptide YY
###end title 40
###begin p 41
###xml 60 62 56 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 121 123 113 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 281 283 273 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 292 294 284 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 311 313 303 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 322 324 314 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 340 341 332 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 367 369 359 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 386 388 378 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 519 521 511 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 530 532 522 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 550 552 542 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 561 563 553 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 646 648 638 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 656 658 648 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 675 677 667 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 685 687 677 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 759 761 751 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 769 771 761 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 805 807 797 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 815 817 807 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 867 868 859 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 1011 1020 1003 1012 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0&#8211;120 min</sub>
###xml 1067 1069 1055 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1086 1095 1074 1083 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0&#8211;120 min</sub>
###xml 1143 1145 1127 1129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 161 169 <span type="species:ncbi:9606">patients</span>
###xml 448 456 <span type="species:ncbi:9606">patients</span>
###xml 962 970 <span type="species:ncbi:9606">patients</span>
Baseline plasma CCK (8.5 +/- 1.0 versus 6.1 +/- 0.4 pmol/L; P = 0.045) and PYY (22.8 +/- 2.2 versus 15.6 +/- 1.3 pmol/L; P = 0.03) concentrations were higher in patients with delayed GE compared with those with normal GE. The GEC was inversely related to both baseline plasma CCK (r = -0.33; P = 0.04) and PYY (r = -0.36; P = 0.02) (Figure 2). Similarly, plasma CCK (P = 0.03) and PYY (P = 0.02) concentrations were higher at 60 and 120 minutes in patients with delayed GE. The GEC was inversely related to plasma CCK (r = -0.32; P = 0.049) and PYY (r = -0.30; P = 0.06) at 120 minutes, but not at 60 minutes. The absolute changes in plasma CCK (r = 0.40; P = 0.01) and PYY (r = 0.42; P < 0.01) at 60 minutes, as well as the integrated changes in plasma CCK (r = 0.36; P = 0.03) and PYY over 120 minutes (r = 0.38; P = 0.02), were directly related to the GEC (Figure 3). The integrated changes in plasma CCK and PYY, however, were not significantly different in patients with delayed versus normal GE (CCK: AUC 0-120 min: 130 +/- 42 versus 160 +/- 38 pmol/L-minutes, P = 0.61; PYY: AUC 0-120 min: 174 +/- 98 versus 414 +/- 155 pmol/L-minutes, P = 0.16).
###end p 41
###begin p 42
###xml 170 174 170 174 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 195 198 195 198 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
The relationship between the rate of gastric emptying, as assessed by the gastric emptying coefficient (GEC), and baseline plasma concentrations of cholecystokinin (CCK) (a) and peptide YY (PYY) (b).
###end p 42
###begin p 43
###xml 69 73 69 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 94 98 94 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
The relationship between the changes in plasma cholecystokinin (CCK) (a) and peptide YY (PYY) (b) from baseline to 60 minutes and the rate of gastric emptying, as assessed by the gastric emptying coefficient (GEC).
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 619 621 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1030 1031 1030 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1032 1033 1032 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1034 1035 1034 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1036 1037 1036 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1038 1040 1038 1040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1041 1043 1041 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 956 964 <span type="species:ncbi:9606">patients</span>
Whilst we have shown previously that plasma CCK and PYY levels are increased in critically ill patients [28-30] and that CCK and PYY are known to slow GE, the present study is the first to directly demonstrate a relationship between GE and plasma concentrations of CCK and PYY in critical illness. The major observations are that, during critical illness, (a) GE was inversely related to both fasting and postprandial plasma CCK and PYY concentrations but (b) the postprandial increases in plasma CCK and PYY were also directly related to GE. Together with previous studies that have shown that enterogastric hormones [28-30] and feedback responses [27] to small intestinal nutrients are exaggerated in the critically ill, the relationship between enterogastric hormones and GE in the present study supports a putative pathogenesis role of enterogastric hormones in disordered GE during critical illness. However, the weakness of the relationship in these patients when compared with that previously reported in healthy subjects [1,2,4,7,11,12] highlights the complexity of the regulatory mechanisms and further suggests that other factors such as admission diagnosis and medication have a role in disordered GE.
###end p 45
###begin p 46
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 891 893 891 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 894 896 894 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1256 1258 1256 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1259 1261 1259 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1796 1798 1796 1798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
###xml 383 391 <span type="species:ncbi:9606">patients</span>
###xml 736 744 <span type="species:ncbi:9606">patients</span>
###xml 842 850 <span type="species:ncbi:9606">patients</span>
###xml 966 974 <span type="species:ncbi:9606">patients</span>
###xml 1292 1300 <span type="species:ncbi:9606">patients</span>
###xml 1464 1472 <span type="species:ncbi:9606">patients</span>
###xml 1632 1640 <span type="species:ncbi:9606">patients</span>
The substantially higher fasting plasma CCK and PYY concentrations in our critically ill patients with delayed GE are consistent with our previous reports on critically ill patients with feed intolerance [28-30]. The observation that the rate of GE is inversely related to the fasting levels of CCK and PYY suggests that they may contribute to the regulation of GE in critically ill patients. Although the strength of the correlation was only modest, the relationship should not be regarded as weak, as this was a cross-sectional study. The mechanisms underlying the elevated fasting levels of these hormones are unknown. Nutritional deprivation is likely to be relevant since inadequate nutritional support is common in critically ill patients, fasting slows GE even in healthy subjects, and fasting CCK and PYY concentrations are higher in patients with anorexia nervosa and malnutrition [21,22]. The lack of differences in fasting hormonal concentrations between patients with and without nutritional support in the present study suggests that the duration of nutritional deprivation may have been insufficient for this effect to become apparent. Prolonged exposure of nutrients from previous feeds related to coexistent small intestinal hypo-motility [25,45] is an unlikely factor as all patients in the present cohort had been fasted for at least 8 hours. Renal impairment is also unlikely to contribute significantly to our observations as the proportion of patients with renal impairment was small and plasma CCK concentrations in this group did not differ from those with normal renal function. Although the majority of our patients received acid suppression therapy and therefore may have had increased serum gastrin levels, the cross-reactivity between gastrin and CCK is less than 2% [46] and is unlikely to contribute to the elevated CCK concentrations.
###end p 46
###begin p 47
###xml 21 22 21 22 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 23 24 23 24 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 25 26 25 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 27 28 27 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 29 31 29 31 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 32 34 32 34 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 47 49 47 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 604 606 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 607 609 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1167 1169 1167 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1170 1172 1170 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1327 1329 1327 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1330 1332 1330 1332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 221 229 <span type="species:ncbi:9606">patients</span>
###xml 465 473 <span type="species:ncbi:9606">patients</span>
###xml 574 582 <span type="species:ncbi:9606">patients</span>
###xml 1092 1100 <span type="species:ncbi:9606">patients</span>
###xml 1274 1282 <span type="species:ncbi:9606">patients</span>
###xml 1442 1450 <span type="species:ncbi:9606">patients</span>
###xml 1518 1526 <span type="species:ncbi:9606">patients</span>
###xml 1794 1802 <span type="species:ncbi:9606">patients</span>
As observed in lean [1,2,4,7,11,12] and obese [47] healthy subjects, the present study demonstrates a weak but direct relationship between the rate of GE and postprandial increases in plasma CCK and PYY in critically ill patients. This indicates that the release of these hormones is dependent on the amount of nutrient delivered into the small intestine, particularly fat [48]. This observation is at variance with recent findings that suggest that critically ill patients with feed intolerance have higher plasma CCK and PYY release in response to duodenal nutrients than patients who tolerated feeds [28,29]. The reason for the apparent discrepancy is unknown but may relate to the difference in the site of nutrient administration. Given the relatively small gastric nutrient load and high frequency of delayed GE (64%), the existence of the relationship between GE and the hormonal release may simply reflect the level of duodenal nutrient stimulation. This possibility is supported by the observation that the hormonal release in the present study was small and similar to that seen in patients who received duodenal nutrition stimulation during 1 kcal/minute [28,29]. However, the concept of heightened hormonal release from a similar nutrient load in critically ill patients, particularly those with impaired motility [28,29], is also illustrated in the present study by the finding that the overall increase in plasma CCK and PYY in patients with delayed GE was similar to those with normal GE. Therefore, in patients with delayed GE, although only a small amount of nutrient was delivered into the duodenum, the 'increased sensitivity' of the duodenal receptors leads to a greater hormonal release for the given nutrient load. Together, these findings suggest that, in critically ill patients, there is a complex interaction between GE, intestinal nutrients, and hormonal release.
###end p 47
###begin p 48
###xml 34 36 34 36 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 576 578 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 579 581 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
Consistent with our recent study [29], the postprandial release of PYY is related to the release of CCK, which supports the concept that CCK is an important proximal mediator for the release of PYY [9,10]. Furthermore, evidence from animal studies [49] suggests that PYY may be released by direct neural stimulation from nutrients in the proximal intestine, possibly via a neural linkage between the proximal gut to the distal PYY-secreting cells which involves sensory vagal fibres with nicotinic, beta-adrenergic, opioid, and serotonergic synapses and nitric oxide release [49,50].
###end p 48
###begin p 49
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 309 315 <span type="species:ncbi:9606">humans</span>
###xml 432 438 <span type="species:ncbi:9606">humans</span>
###xml 570 578 <span type="species:ncbi:9606">patients</span>
Although blood glucose concentrations were adequately controlled by the standardized insulin therapy, the potential impact of insulin on the enterogastric feedback and the hormonal release is not known. Whilst insulin-induced hypoglycaemia has no significant effect on antro-pyloro-duodenal motor activity in humans [51], it accelerates GE [52]. Currently, there are no data on the impact of insulin on the release of CCK or PYY in humans. In the present study, the effects of insulin on the enterogastric feedback and the hormonal release are likely to be small as all patients received the therapy. In addition, insulin is essential in this study as it minimized the adverse impact of hyperglycaemia on the rate of GE.
###end p 49
###begin p 50
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 469 471 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 487 495 <span type="species:ncbi:9606">patients</span>
###xml 618 624 <span type="species:ncbi:9606">humans</span>
Whilst the present observations strengthen the rationale for the potential use of CCK antagonists in the management of feed intolerance in the critically ill, it should be recognised that the efficacy of such agents may be limited due to the complex interaction amongst many factors that regulate GE during critical illness. Despite this reservation, loxiglumide (a CCK antagonist) has been shown to accelerate the GE of lipid-rich liquid meals in healthy subjects [17-19,53] as well as patients with functional dyspepsia [54] and irritable bowel syndrome [55]. Currently, PYY antagonists are not available for use in humans.
###end p 50
###begin title 51
Conclusion
###end title 51
###begin p 52
During critical illness, the relationship between GE, plasma CCK, and PYY is complex. Whilst GE is inversely related to fasting and postprandial plasma CCK and PYY concentrations, it may also be a determinant of CCK and PYY response to a meal. The role of these enterogastric hormones in the pathogenesis of impaired GE during critical illness, however, requires further evaluation with specific antagonists.
###end p 52
###begin title 53
Key messages
###end title 53
###begin p 54
###xml 178 186 <span type="species:ncbi:9606">patients</span>
###xml 307 315 <span type="species:ncbi:9606">patients</span>
* Although enterogastric feedback in response to nutrient is enhanced and plasma concentrations of both cholecystokinin (CCK) and peptide YY (PYY) are elevated in critically ill patients, the relationships between plasma CCK and PYY concentrations and gastric emptying (GE) have not been evaluated in these patients.
###end p 54
###begin p 55
* This study is the first to establish the complex relationship between GE and plasma concentrations of CCK and PYY in critical illness.
###end p 55
###begin p 56
* The major observations of this study are that during critical illness:
###end p 56
###begin p 57
###xml 52 60 <span type="species:ncbi:9606">patients</span>
i. plasma CCK and PYY concentrations were higher in patients with delayed GE, during both fasting and for 2 hours postprandially, and
###end p 57
###begin p 58
ii. GE was inversely related to both fasting and postprandial plasma CCK and PYY concentrations, but the postprandial increases in plasma CCK and PYY were also directly related to GE.
###end p 58
###begin p 59
* Whilst these findings support the potential role of these enterogastric hormones in the pathogenesis of impaired GE during critical illness, further evaluation with specific antagonists is warranted.
###end p 59
###begin title 60
Abbreviations
###end title 60
###begin p 61
###xml 90 100 90 100 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0&#8211;120 min </sub>
ANOVA = analysis of variance; APACHE = Acute Physiology and Chronic Health Evaluation; AUC0-120 min = area under curve over the course of 120 minutes; BMI = body mass index; CCK = cholecystokinin; GE = gastric emptying; GEC = gastric emptying coefficient; ICU = intensive care unit; PYY = peptide YY.
###end p 61
###begin title 62
Competing interests
###end title 62
###begin p 63
The authors declare that they have no competing interests.
###end p 63
###begin title 64
Authors' contributions
###end title 64
###begin p 65
###xml 167 175 <span type="species:ncbi:9606">patients</span>
###xml 539 547 <span type="species:ncbi:9606">patients</span>
NQN participated in the study design, carried out the studies and performed data and statistical analysis, helped draft the manuscript, and was involved in recruiting patients from the ICU of the Royal Adelaide Hospital. RJF, RHH, and MH helped conceive the study, participated in its design and coordination, and helped draft the manuscript. LKB helped carry out the studies and collection of data and helped draft the manuscript. MJC helped conceive the study, participated in its design and coordination, and was involved in recruiting patients from the ICU of the Royal Adelaide Hospital. JW performed the radioimmunoassay. RB was responsible for analysing GE breath samples. All authors read and approved the final manuscript.
###end p 65
###begin title 66
Acknowledgements
###end title 66
###begin p 67
This work was performed at the Royal Adelaide Hospital, South Australia, and was supported, in part, by a project grant (349329) from the National Health and Medical Research Council (NHMRC) of Australia. NQN is an NHMRC Clinical Research Fellow.
###end p 67
###begin article-title 68
Cholecystokinin inhibits gastric emptying by acting on both proximal stomach and pylorus
###end article-title 68
###begin article-title 69
###xml 79 85 <span type="species:ncbi:9606">humans</span>
Role of cholecystokinin as a regulator of solid and liquid gastric emptying in humans
###end article-title 69
###begin article-title 70
###xml 62 65 <span type="species:ncbi:9606">man</span>
Cholecystokinin octapeptide decreases intake of solid food in man
###end article-title 70
###begin article-title 71
Effects of cholecystokinin on appetite and pyloric motility during physiological hyperglycemia
###end article-title 71
###begin article-title 72
###xml 64 67 <span type="species:ncbi:9606">man</span>
Effects of peptide YY and neuropeptide Y on gastric emptying in man
###end article-title 72
###begin article-title 73
Duodenal acidification releases cholecystokinin
###end article-title 73
###begin article-title 74
###xml 34 40 <span type="species:ncbi:9606">humans</span>
Regulation of gastric emptying in humans by cholecystokinin
###end article-title 74
###begin article-title 75
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human distribution and release of a putative new gut hormone, peptide YY
###end article-title 75
###begin article-title 76
Release of distal gut peptide YY (PYY) by fat in proximal gut depends on CCK
###end article-title 76
###begin article-title 77
Postprandial peptide YY release is mediated by cholecystokinin
###end article-title 77
###begin article-title 78
###xml 84 90 <span type="species:ncbi:9606">humans</span>
Cholecystokinin octapeptide stimulates phasic and tonic pyloric motility in healthy humans
###end article-title 78
###begin article-title 79
Effects of age on concentrations of plasma cholecystokinin, glucagon-like peptide 1, and peptide YY and their relation to appetite and pyloric motility
###end article-title 79
###begin article-title 80
Gut hormone PYY(3-36) physiologically inhibits food intake
###end article-title 80
###begin article-title 81
The putative satiety hormone PYY is raised in cardiac cachexia associated with primary pulmonary hypertension
###end article-title 81
###begin article-title 82
Peptide YY, appetite and food intake
###end article-title 82
###begin article-title 83
Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively
###end article-title 83
###begin article-title 84
###xml 93 99 <span type="species:ncbi:9606">humans</span>
Role of cholecystokinin in the regulation of liquid gastric emptying and gastric motility in humans: studies with the CCK antagonist loxiglumide
###end article-title 84
###begin article-title 85
###xml 101 107 <span type="species:ncbi:9606">humans</span>
Effect of lintitript, a new CCK-A receptor antagonist, on gastric emptying of a solid-liquid meal in humans
###end article-title 85
###begin article-title 86
###xml 97 103 <span type="species:ncbi:9606">humans</span>
Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide
###end article-title 86
###begin article-title 87
###xml 18 21 <span type="species:ncbi:10116">rat</span>
Starvation in the rat: effect on peptides of the gut and brain
###end article-title 87
###begin article-title 88
Disturbed release of gastrointestinal peptides in anorexia nervosa and in obesity
###end article-title 88
###begin article-title 89
Plasma and brain cholecystokinin levels in cancer anorexia
###end article-title 89
###begin article-title 90
Delayed gastric emptying in anorexia nervosa is improved by completion of a renutrition program
###end article-title 90
###begin article-title 91
###xml 20 28 <span type="species:ncbi:9606">patients</span>
Gastric emptying in patients with bulimia nervosa and anorexia nervosa
###end article-title 91
###begin article-title 92
###xml 20 28 <span type="species:ncbi:9606">patients</span>
GI complications in patients receiving mechanical ventilation
###end article-title 92
###begin article-title 93
The link between nutritional status and clinical outcome: can nutritional intervention modify it?
###end article-title 93
###begin article-title 94
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Antro-pyloro-duodenal motor responses to gastric and duodenal nutrient in critically ill patients
###end article-title 94
###begin article-title 95
Feed intolerance in critical illness is associated with increased basal and nutrient-stimulated plasma cholecystokinin concentrations
###end article-title 95
###begin article-title 96
Fasting and nutrient-stimulated plasma peptide-YY levels are elevated in critical illness and associated with feed intolerance: an observational, controlled study
###end article-title 96
###begin article-title 97
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Changes in appetite related gut hormones in intensive care unit patients: a pilot cohort study
###end article-title 97
###begin article-title 98
###xml 110 118 <span type="species:ncbi:9606">patients</span>
Proximal gastric response to small intestinal nutrients is abnormal in mechanically ventilated critically ill patients
###end article-title 98
###begin article-title 99
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Gastroduodenal motility in mechanically ventilated critically ill patients: a manometric study
###end article-title 99
###begin article-title 100
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Delayed gastric emptying in ventilated critically ill patients: measurement by 13 C-octanoic acid breath test
###end article-title 100
###begin article-title 101
Gastric emptying of a solid-liquid meal measured with 13C octanoic acid breath test and real-time ultrasonography: a comparative study
###end article-title 101
###begin article-title 102
[13C]octanoic acid breath test for gastric emptying of solids: accuracy, reproducibility, and comparison with scintigraphy
###end article-title 102
###begin article-title 103
Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test
###end article-title 103
###begin article-title 104
Gastric emptying time of fluids and solids in healthy subjects determined by 13C breath tests: influence of age, sex and body mass index
###end article-title 104
###begin article-title 105
13C-Octanoic acid breath test for gastric emptying rate of solids
###end article-title 105
###begin article-title 106
Measuring gastric emptying: comparison of 13C-octanoic acid breath test and scintigraphy
###end article-title 106
###begin article-title 107
###xml 101 109 <span type="species:ncbi:9606">patients</span>
The role of 13C-octanoic acid breath testing in the assessment of gastric emptying in critically ill patients
###end article-title 107
###begin article-title 108
APACHE II score in massive upper gastrointestinal haemorrhage from peptic ulcer: prognostic value and potential clinical applications
###end article-title 108
###begin article-title 109
[*C]octanoic acid breath test to measure gastric emptying rate of solids
###end article-title 109
###begin article-title 110
Physical state of meal affects gastric emptying, cholecystokinin release and satiety
###end article-title 110
###begin article-title 111
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Erythromycin improves gastric emptying in critically ill patients intolerant of nasogastric feeding
###end article-title 111
###begin article-title 112
###xml 55 61 <span type="species:ncbi:9606">humans</span>
Effect of short-term starvation on gastric emptying in humans: relationship to oral glucose tolerance
###end article-title 112
###begin article-title 113
###xml 131 134 <span type="species:ncbi:9606">men</span>
Effects of load, and duration, of duodenal lipid on antropyloroduodenal motility, plasma CCK and PYY, and energy intake in healthy men
###end article-title 113
###begin article-title 114
###xml 91 97 <span type="species:ncbi:9606">people</span>
Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people
###end article-title 114
###begin article-title 115
Intestinal fat-induced inhibition of meal-stimulated gastric acid secretion depends on CCK but not peptide YY
###end article-title 115
###begin article-title 116
Evidence for regulation of peptide-YY release by the proximal gut
###end article-title 116
###begin article-title 117
Slowing of intestinal transit by fat or peptide YY depends on beta-adrenergic pathway
###end article-title 117
###begin article-title 118
Effect of insulin-induced hypoglycaemia on antral, pyloric and duodenal motility in fasting subjects
###end article-title 118
###begin article-title 119
Insulin-induced hypoglycemia accelerates gastric emptying of solids and liquids in long-standing type 1 diabetes
###end article-title 119
###begin article-title 120
###xml 88 92 <span type="species:ncbi:10116">rats</span>
PYY immunoneutralization does not alter lipid-induced inhibition of gastric emptying in rats
###end article-title 120
###begin article-title 121
Clinical efficacy and prokinetic effect of the CCK-A antagonist loxiglumide in nonulcer dyspepsia
###end article-title 121
###begin article-title 122
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study
###end article-title 122

